Interestingly, PD-0325901 (an investigational MEK inhibitor [23]), PD-184352 (an investigational MAPK inhibitor [24]) and KU 0060648 trihydrochloride were predicted to reverse gene expression patterns of all glomerular diseases (Table 2). This evidence concerns the gene MAP2K7 and glomerular disorder.